Ignite Creation Date:
2024-05-06 @ 6:18 PM
Last Modification Date:
2024-10-26 @ 2:45 PM
Study NCT ID:
NCT05619913
Status:
RECRUITING
Last Update Posted:
2024-02-08
First Post:
2022-10-26
Brief Title:
EPOCH Eribulin and Pembrolizumab in OvarianUterine Carcinosarcoma
Sponsor:
Australia New Zealand Gynaecological Oncology Group
Organization:
Australia New Zealand Gynaecological Oncology Group
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-05-22
Start Date Type:
ACTUAL
Primary Completion Date:
2024-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12
Completion Date Type:
ESTIMATED
First Submit Date:
2022-10-26
First Submit QC Date:
November 9 2022
Study First Post Date:
2022-11-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-02-06
Last Update Post Date:
2024-02-08
Last Update Post Date Type:
ACTUAL